Just H M, Becker C, Bassler M, Daschner F D
Chemotherapy. 1984;30(6):387-91. doi: 10.1159/000238298.
The in vitro efficacy of cefotetan in combination with gentamicin, tobramycin, amikacin, netilmicin against Staphylococcus aureus, Staphylococcus epidermidis and Enterobacter cloacae and with piperacillin and mezlocillin against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae was compared by use of the checkerboard agar dilution technique. On average, 60% of the gram-negative and 46% of the gram-positive strains were inhibited by additive, but only 22% of the gram-negative and 2% of the gram-positive bacteria were inhibited by synergistic cefotetan-aminoglycoside combinations. Netilmicin combinations were least active. On gram-negative bacteria, 63% of the cefotetan-penicillin combinations were additive and 11% synergistic. No antagonism occurred with any of the combinations.
采用棋盘琼脂稀释技术比较了头孢替坦分别与庆大霉素、妥布霉素、阿米卡星、奈替米星联合对金黄色葡萄球菌、表皮葡萄球菌和阴沟肠杆菌的体外抗菌效果,以及与哌拉西林和美洛西林联合对大肠杆菌、肺炎克雷伯菌、粘质沙雷氏菌和阴沟肠杆菌的体外抗菌效果。平均而言,60%的革兰氏阴性菌和46%的革兰氏阳性菌被头孢替坦与氨基糖苷类药物的相加作用所抑制,但只有22%的革兰氏阴性菌和2%的革兰氏阳性菌被头孢替坦-氨基糖苷类药物的协同组合所抑制。奈替米星联合用药的活性最低。在革兰氏阴性菌方面,63%的头孢替坦-青霉素联合用药表现为相加作用,11%为协同作用。所有联合用药均未出现拮抗作用。